Impact of VP1-specific protein sequence motifs on adeno-associated virus type 2 intracellular trafficking and nuclear entry

Journal of Virology

Volumn 86, Issue 17, 2012, Pages 9163-9174

  Popa Wagner, Ruth ^a   Porwal, Manvi ^b   Kann, Michael ^c   Reuss, Matthias ^a   Weimer, Marc ^a   Florin, Luise ^d   Kleinschmidt, Jürgen A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c University Victor Segalen   (France)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPASE A2; PROTEIN VP1; PROTEIN VP2;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS TYPE 2; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; DILEUCINE MOTIF; ENDOSOME; ENZYME ACTIVITY; FHA BINDING MOTIF; GENE MUTATION; GENETIC CONSERVATION; IN VITRO STUDY; INTRACELLULAR SIGNALING; INTRACELLULAR TRANSPORT; MUTANT; MUTATIONAL ANALYSIS; NONHUMAN; PDZ DOMAIN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INTERACTION; PROTEIN MOTIF; SEROTYPE; SH2 BINDING MOTIF; SH3 BINDING MOTIF; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS ENTRY; VIRUS INFECTIVITY; WILD TYPE; YXXQ SEQUENCE MOTIF;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; CAPSID PROTEINS; CELL LINE; CELL NUCLEUS; DEPENDOVIRUS; HUMANS; MOLECULAR SEQUENCE DATA; PARVOVIRIDAE INFECTIONS; PROTEIN TRANSPORT; SEQUENCE ALIGNMENT;

ADENO-ASSOCIATED VIRUS - 2; EUKARYOTA; MIRIDAE;

EID: 84866152302     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00282-12     Document Type: Article

References (64)

1. Akache B, et al. 2006. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J. Virol. 80:9831-9836.
2. Akache B, et al. 2007. A two-hybrid screen identifies cathepsins B and L as uncoating factors for adeno-associated virus 2 and 8. Mol. Ther. 15:330-339.
3. Aniento F, Gruenberg J. 2004. Subcellular fractionation of tissue culture cells. Current Protoc. Protein Sci. Chapter 4:Unit 4.3.
4. Asokan A, Hamra JB, Govindasamy L, Agbandje-McKenna M, Samulski RJ. 2006. Adeno-associated virus type 2 contains an integrin α5β1 binding domain essential for viral cell entry. J. Virol. 80:8961-8969.
5. Bartlett JS, Wilcher R, Samulski RJ. 2000. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J. Virol. 74:2777-2785.
6. Bleker S, Sonntag F, Kleinschmidt JA. 2005. Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity. J. Virol. 79:2528-2540.
7. Cohen S, Behzad AR, Carroll JB, Pante N. 2006. Parvoviral nuclear import: bypassing the host nuclear-transport machinery. J. Gen. Virol. 87:3209-3213.
8. Cohen S, Marr AK, Garcin P, Pante N. 2011. Nuclear envelope disruption involving host caspases plays a role in the parvovirus replication cycle. J. Virol. 85:4863-4874.
9. Cohen S, Pante N. 2005. Pushing the envelope: microinjection of Minute virus of mice into Xenopus oocytes causes damage to the nuclear envelope. J. Gen. Virol. 86:3243-3252.
10. Daya S, Berns KI. 2008. Gene therapy using adeno-associated virus vectors. Clin. Microbiol. Rev. 21:583-593.
11. Ding W, Zhang L, Yan Z, Engelhardt JF. 2005. Intracellular trafficking of adeno-associated viral vectors. Gene Ther. 12:873-880.
12. Ding W, Zhang LN, Yeaman C, Engelhardt JF. 2006. rAAV2 traffics through both the late and the recycling endosomes in a dose-dependent fashion. Mol. Ther. 13:671-682.
13. Douar AM, Poulard K, Stockholm D, Danos O. 2001. Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J. Virol. 75:1824-1833.
14. Duan D, et al. 1999. Dynamin is required for recombinant adenoassociated virus type 2 infection. J. Virol. 73:10371-10376.
15. Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF. 2000. Endosomal processing limits gene transfer to polarized airway epithelia by adenoassociated virus. J. Clin. Invest. 105:1573-1587.
16. Farr GA, Zhang LG, Tattersall P. 2005. Parvoviral virions deploy a capsid-tethered lipolytic enzyme to breach the endosomal membrane during cell entry. Proc. Natl. Acad. Sci. U. S. A. 102:17148-17153.
17. Girod A, et al. 2002. The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J. Gen. Virol. 83:973-978.
18. Gorvel JP, Chavrier P, Zerial M, Gruenberg J. 1991. rab5 controls early endosome fusion in vitro. Cell 64:915-925.
19. Grieger JC, Snowdy S, Samulski RJ. 2006. Separate basic region motifs within the adeno-associated virus capsid proteins are essential for infectivity and assembly. J. Virol. 80:5199-5210.
20. Grimm D, et al. 1999. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 6:1322-1330.
21. Hansen J, Qing K, Kwon HJ, Mah C, Srivastava A. 2000. Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J. Virol. 74:992-996.
22. Hansen J, Qing K, Srivastava A. 2001. Adeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction efficiency in murine fibroblasts. J. Virol. 75:4080-4090.
23. Hansen J, Qing K, Srivastava A. 2001. Infection of purified nuclei by adeno-associated virus 2. Mol. Ther. 4:289-296.
24. Harris BZ, Lim WA. 2001. Mechanism and role of PDZ domains in signaling complex assembly. J. Cell Sci. 114:3219-3231.
25. Hauck B, Zhao W, High K, Xiao W. 2004. Intracellular viral processing, not single-stranded DNA accumulation, is crucial for recombinant adenoassociated virus transduction. J. Virol. 78:13678-13686.
26. Heilbronn R, Burkle A, Stephan S, Hausen H. 1990. The adenoassociated virus rep gene suppresses herpes simplex virus-induced DNA amplification. J. Virol. 64:3012-3018.
27. Hoque M, et al. 1999. Nuclear transport of the major capsid protein is essential for adeno-associated virus capsid formation. J. Virol. 73:7912-7915.
28. Javier RT, Rice AP. 2011. Emerging theme: cellular PDZ proteins as common targets of pathogenic viruses. J. Virol. 85:11544-11556.
29. Johnson JS, et al. 2010. Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. J. Virol. 84:8888-8902.
30. Johnson JS, Samulski RJ. 2009. Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J. Virol. 83:2632-2644.
31. Kashiwakura Y, et al. 2005. Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J. Virol. 79:609-614.
32. Kern A, et al. 2003. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J. Virol. 77:11072-11081.
33. Kobayashi T, et al. 2002. Separation and characterization of late endosomal membrane domains. J. Biol. Chem. 277:32157-32164.
34. Kronenberg S, Bottcher B, von der Lieth CW, Bleker S, Kleinschmidt JA. 2005. A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J. Virol. 79:5296-5303.
35. Laughlin CA, Tratschin JD, Coon H, Carter BJ. 1983. Cloning of infectious adeno-associated virus genomes in bacterial plasmids. Gene 23:65-73.
36. Li C, Bowles DE, van Dyke T, Samulski RJ. 2005. Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther. 12:913-925.
37. Lux K, et al. 2005. Green fluorescent protein-tagged adeno-associated virus particles allow the study of cytosolic and nuclear trafficking. J. Virol. 79:11776-11787.
38. Mueller C, Flotte TR. 2008. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther. 15:858-863.
39. Muzyczka N, Berns KI. 2001. Parvoviridae: the viruses and their replication, p 2327-2360. In Knipe DM, Howley PM(ed), Fields virology, 4th ed. Lippincott/The Williams & Wilkins Co, New York, NY.
40. Naldini L, et al. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267.
41. Nieto K, et al. 2009. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adenoassociated virus serotype vectors. Antivir. Ther. 14:1125-1137.
42. Nonnenmacher M, Weber T. 2011. Adeno-associated virus 2 infection requires endocytosis through the CLIC/GEEC pathway. Cell Host Microbe 10:563-576.
43. Nourry C, Grant SG, Borg JP. 2003. PDZ domain proteins: plug and play! Sci. STKE 2003:RE7.
44. Pajusola K, et al. 2002. Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells. J. Virol. 76:11530-11540.
45. Parrish CR. 2010. Structures and functions of parvovirus capsids and the process of cell infection. Curr. Top. Microbiol. Immunol. 343:149-176.
46. Qing K, et al. 1999. Human fibroblast growth factor receptor 1 is a coreceptor for infection by adeno-associated virus 2. Nat. Med. 5:71-77.
47. Sanlioglu S, et al. 2000. Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation. J. Virol. 74:9184-9196.
48. Scott JD, Pawson T. 2009. Cell signaling in space and time: where proteins come together and when they're apart. Science 326:1220-1224.
49. Seisenberger G, et al. 2001. Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science 294:1929-1932.
50. Sonntag F, Bleker S, Leuchs B, Fischer R, Kleinschmidt JA. 2006. Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J. Virol. 80:11040-11054.
51. Stahnke S, et al. 2011. Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles. Virology 409:77-83.
52. Studier FW. 2005. Protein production by auto-induction in high-density shaking cultures. Protein Expr. Purif. 41:207-234.
53. Summerford C, Bartlett JS, Samulski RJ. 1999. αvβ5 integrin: a coreceptor for adeno-associated virus type 2 infection. Nat. Med. 5:78-82.
54. Summerford C, Samulski RJ. 1998. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72:1438-1445.
55. Vandenberghe LH, Wilson JM, Gao G. 2009. Tailoring the AAV vector capsid for gene therapy. Gene Ther. 16:311-319.
56. Veldwijk MR, et al. 2002. Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol. Ther. 6:272-278.
57. Wistuba A, Kern A, Weger S, Grimm D, Kleinschmidt JA. 1997. Subcellular compartmentalization of adeno-associated virus type 2 assembly. J. Virol. 71:1341-1352.
58. Wistuba A, Weger S, Kern A, Kleinschmidt JA. 1995. Intermediates of adeno-associated virus type 2 assembly: identification of soluble complexes containing Rep and Cap proteins. J. Virol. 69:5311-5319.
59. Wu P, et al. 2000. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74:8635-8647.
60. Xiao W, Warrington KH, Jr, Hearing P, Hughes J, Muzyczka N. 2002. Adenovirus-facilitated nuclear translocation of adeno-associated virus type 2. J. Virol. 76:11505-11517.
61. Xiao X, Li J, Samulski RJ. 1998. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72:2224-2232.
62. Zadori Z, et al. 2001. A viral phospholipase A2 is required for parvovirus infectivity. Dev. Cell 1:291-302.
63. Zhong L, et al. 2004. Impaired nuclear transport and uncoating limit recombinant adeno-associated virus 2 vector-mediated transduction of primary murine hematopoietic cells. Hum. Gene Ther. 15:1207-1218.
64. Zhong L, et al. 2007. A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol. Ther. 15:1323-1330.